Overview

Ceramide NanoLiposome in Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Keystone Nano, Inc
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)